Germline RAD51C mutations in ovarian cancer susceptibility

Clinical Genetics

Volumn 83, Issue 4, 2013, Pages 332-336

  Coulet, F ^a   Fajac, A ^b   Colas, C ^a   Eyries, M ^a   Dion Miniere A ^a   Rouzier, R ^b   Uzan, S ^b   Lefranc, J P ^a   Carbonnel, M ^c   Cornelis, F ^c   Cortez, A ^b   Soubrier, F ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL JEAN VERDIER   (France)

Author keywords

Breast cancer susceptibility; Germline mutation; Ovarian cancer susceptibility; RAD51C

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; HUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PEDIGREE ANALYSIS; PRIORITY JOURNAL; RAD51C GENE; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; MALE; MIDDLE AGED; OVARY TUMOR;

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA BINDING PROTEIN; RAD51C PROTEIN, HUMAN;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 84874955840     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2012.01917.x     Document Type: Article

References (17)

1. McClellan J, King MC. Genetic heterogeneity in human disease. Cell 2010: 141: 210-217.
2. Rafnar T, Gudbjartsson DF, Sulem P et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011: 43: 1104-1107.
3. Loveday C, Turnbull C, Ramsay E et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011: 43: 879-882.
4. Osher DJ, De Leeneer K, Michils G et al. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. Br J Cancer 2012: 106: 1460-1463.
5. Wong MW, Nordfors C, Mossman D et al. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat 2011: 127: 853-859.
6. Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010: 42: 410-414.
7. Akbari MR, Tonin P, Foulkes WD, Ghadirian P, Tischkowitz M, Narod SA. RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res 2010: 12: 404.
8. Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat 2010: 124: 857-861.
9. Johnson J, Healey S, Khanna KK, Chenevix-Trench G. Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families. Breast Cancer Res Treat 2011: 129: 255-263.
10. Romero A, Perez-Segura P, Tosar A et al. A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. Breast Cancer Res Treat 2011: 129: 939-946.
11. Pelttari LM, Heikkinen T, Thompson D et al. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 2011: 20: 3278-3288.
12. Thompson ER, Boyle SE, Johnson J et al. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat 2012: 33: 95-99.
13. Coulet F, Pires F, Rouleau E et al. A one-step prescreening for point mutations and large rearrangement in BRCA1 and BRCA2 genes using quantitative polymerase chain reaction and high-resolution melting curve analysis. Genet Test Mol Biomarkers 2010: 14: 677-690.
14. Silvestri V, Rizzolo P, Falchetti M et al. Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res 2011: 13: 404.
15. Loveday C, Turnbull C, Ruark E et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012: 44: 475-476.
16. Walsh T, Casadei S, Lee MK et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011: 108: 18032-18037.
17. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009: 361: 123-134.